Table 1.
Immune-based assays developed against different SARS-CoV-2 viral proteins.
| Antigen | Antibody | Sample type | Specificity | References | |
|---|---|---|---|---|---|
| Spike (S) | Entire S | IgM, IgG | Patient serum | Not reported | (10, 11) |
| IgG | Patient serum | Cross-react with SARS-CoV and MERS-CoV | (14) | ||
| Not indicated | Patient plasma | Cross-react with SARS-CoV | (19) | ||
| IgM, IgG, IgA | Patient serum or plasma | Not reported | (13) | ||
| S1 subunit | IgG, IgA | Patient serum | Cross-react with SARS-CoV only | (14) | |
| S2 subunit | Not indicated | Patient plasma | Not reported | (19) | |
| Receptor-binding domain (RBD) | IgG | Patient serum | Cross-react with SARS-CoV only | (14) | |
| Not indicated | Patient plasma | Cross-react with SARS-CoV | (19) | ||
| IgG | Mouse serum | SARS-CoV RBD-induced antibodies cross-react to SARS-CoV-2 RBD | (20) | ||
| IgM, IgG, IgA | Patient serum or plasma | Not reported | (13) | ||
| Nucleocapsid (N) | IgG | Patient serum | Cross-react with SARS-CoV only | (14) | |